Antibody conjugates

US6197299A · kind A · utility

Assignee

• Pharmacia & UpJohn AB · SE

Inventors

• Mikael Dohlsten · Lund, SE
• Eva Akerblom · Uppsala, SE
• Peter Lando · Malmö, SE
• Terje Kalland · Arese, IT
• Gunnar Hedlund · Lund, SE

Key dates

• Filing date: Sep 16, 1998
• Grant date: Mar 6, 2001
• Expiry date: Sep 16, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/627
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A soluble antibody conjugate comprising an antibody linked to a structure which is recognized by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regime for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.